The performance of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the loss of exclusivity in key markets has introduced significant risk . Investors are now assessing the impact of lower-cost alterna